Divi's LaboratoriesNSE:DIVISLAB -0.59%94 Days Payable is 98.75 as of Mar. 2026, which is 10% above its 10-year median of 89.65. GuruFocus rates NSE:DIVISLAB with a GF Score™ of 94/100 and a GF Value™ of ₹6,732.51 (Fairly Valued). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, Divi's Laboratories ranks better than 52.33% on this metric.
The historical rank and industry rank for Divi's Laboratories's Days Payable or its related term are showing as below:
NSE:DIVISLAB'
s Days Payable Range Over the Past 10 Years
Min: 77.29 Med: 89.65 Max: 101.57
Current: 93.96
During the past 13 years, Divi's Laboratories's highest Days Payable was 101.57. The lowest was 77.29. And the median was 89.65.
NSE:DIVISLAB's Days Payable is ranked better than 52.33% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs NSE:DIVISLAB: 93.96
Divi's Laboratories's Days Payable
increased
from Mar. 2025 (84.65) to Mar. 2026 (98.75).
It may suggest that Divi's Laboratoriesdelayed paying its suppliers.
Divi's Laboratories Days Payable Related Terms
Divi's Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Divi's Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Divi's Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Divi's Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Divi's Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Divi's Laboratories (NSE:DIVISLAB) has a Days Payable of 98.75 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Divi's Laboratories and its competitors. This is 10% above median its historical median of 89.65. Over the past decade, Divi's Laboratories' Days Payable has ranged from 77.29 to 101.57. According to the industry distribution chart, Divi's Laboratories ranks #440 out of 923 companies in the Drug Manufacturers industry, placing it in the top 47.7%.
Is Divi's Laboratories' Days Payable too high?
Divi's Laboratories' current Days Payable of 98.75 is 10% above median its 10-year median of 89.65. Over the past 10 years, this metric has ranged from a low of 77.29 to a high of 101.57. The Drug Manufacturers industry median Days Payable is 90.98. Divi's Laboratories' value of 98.75 is 8.5% above this industry median. Based on the distribution chart, Divi's Laboratories ranks #440 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Divi's Laboratories has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Divi's Laboratories ranks #440 out of 923 companies for Days Payable. This puts Divi's Laboratories in the upper half of its industry. The industry median Days Payable is 90.98. Divi's Laboratories' value of 98.75 is 8.5% above this benchmark. Historically, Divi's Laboratories' own Days Payable has ranged from 77.29 to 101.57 over the past decade. While the company's 10-year median is 89.65 vs. the industry median of 90.98, Divi's Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Divi's Laboratories's current Days Payable of 98.75 is 8.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Divi's Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Divi's Laboratories's current Days Payable is 98.75, which is 10% above median its own 10-year median of 89.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,732.51, compared to a current price of ₹6,713.50 — trading 0.3% below its estimated fair value. The current Days Payable is 98.75, which is 10% above median its 10-year median of 89.65 and 8.5% above the Drug Manufacturers industry median of 90.98. Divi's Laboratories' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current Days Payable is 98.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Divi's Laboratories stock appears to be undervalued.
The current stock price of ₹6,713.50 is trading 0.3% below its estimated GF Value™ of ₹6,732.51.
GuruFocus considers Divi's Laboratories to be Fairly Valued.
Key valuation signals for NSE:DIVISLAB:
Days Payable: 98.75 (10% above median its 10-year median of 89.65)
GF Value™: ₹6,732.51 vs. price of ₹6,713.50 (0.3% below fair value)
Industry Position: 8.5% above the Drug Manufacturers median (#440 of 923)
No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
94GF Score
Get the complete analysis for NSE:DIVISLAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DIVISLAB has been successfully added to your 
